Phase pharmacokinetic trial intraperitoneal etoposide combination multidrug-resistance-modulating agent dipyridamole Dipyridamole sensitivity human ovarian carcinoma cells vitro phase trial feasibility dipyridamole sensitivity tumors peritoneal cavity Etoposide dipyridamole continuous intraperitoneal infusion patients maximum dose etoposide day dipyridamole fixed dose day Dose-limiting toxic effects leukopenia thrombocytopenia major toxic effects free peritoneal etoposide dipyridamole concentrations etoposide dose rate microM etoposide dose rate day free etoposide dipyridamole concentrations range synergistic interaction 